AbbVie

Who will be the biggest pharma players in orphan drugs?
Who will be the biggest pharma players in orphan drugs?
Pharmaforum
orphan drugs
Roche
M&A
AbbVie
JNJ
Flag link:
Skyrizi looks ready to soar after strong launch
Skyrizi looks ready to soar after strong launch
Biopharma Dive
AbbVie
Skyrizi
psoriasis
Flag link:
Rova-T: the story of AbbVie’s multi-billion dollar failure
Rova-T: the story of AbbVie’s multi-billion dollar failure
Pharmaforum
AbbVie
lung cancer
M&A
Stemcentrx
Rova-T
Flag link:
$5.8B for Nothing: AbbVie Shelves Stemcentryx Drug After Latest Flop
$5.8B for Nothing: AbbVie Shelves Stemcentryx Drug After Latest Flop
Xconomy
AbbVie
Stemcentryx
Rova-T
Flag link:
FDA issues safety warning for newer hepatitis C drugs following patient deaths
FDA issues safety warning for newer hepatitis C drugs following patient deaths
Biopharma Dive
FDA
hepatitis C
FAERS
AbbVie
Mavyret
Merck
Zepatier
Gilead Sciences
Vosevi
Flag link:
Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen
Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen
Endpoints
Bristol-Myers Squibb
AbbVie
Empliciti
Celgene
Europe
relapsed or refractory multiple myeloma
Flag link:
AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira
AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira
Motley Fool
AbbVie
Rinvoq
Humira
immunology
Flag link:
AbbVie's Rinvoq label portends safety warnings for future JAKs—including Gilead's
AbbVie's Rinvoq label portends safety warnings for future JAKs—including Gilead's
Fierce Pharma
JAK inhibitors
AbbVie
Rinvoq
FDA
Gilead Sciences
Flag link:
Price, safety will test blockbuster billing for AbbVie's new arthritis drug
Price, safety will test blockbuster billing for AbbVie's new arthritis drug
Biopharma Dive
AbbVie
rheumatoid arthritis
drug pricing
Rinvoq
Flag link:
Rinvoq approval bolsters AbbVie's autoimmune portfolio
Rinvoq approval bolsters AbbVie's autoimmune portfolio
BioCentury
AbbVie
FDA
Rinvoq
Upadacitinib
rheumatoid arthritis
Flag link:
Four New Drugs are Around the Corner. Here’s What You Need to Know.
Four New Drugs are Around the Corner. Here’s What You Need to Know.
Xconomy
FDA
drug approvals
AbbVie
Upadacitinib
Exondys 51
Sarepta Therapeutics
Nabriva Therapeutics
lefamulin
Roche
Rozlytrek
Flag link:
Allergan CEO Saunders lines up for $39M parachute after AbbVie buy
Allergan CEO Saunders lines up for $39M parachute after AbbVie buy
Fierce Pharma
Allergan
executive pay
Pharma CEOs
Brent Saunders
AbbVie
M&A
Flag link:
Table for two: AbbVie was Allergan's only suitor in $63B takeover that shocked the industry
Table for two: AbbVie was Allergan's only suitor in $63B takeover that shocked the industry
Fierce Pharma
AbbVie
Allergan
M&A
Flag link:
5 Biggest New Drugs Approved in 2019 So Far
5 Biggest New Drugs Approved in 2019 So Far
Motley Fool
drug approvals
FDA
AbbVie
JNJ
Novartis
Pfizer
Skyrizi
psoriasis
Vyndaqel
Zolgensma
SMA
Mayzent
multiple sclerosis
Balversa
metastatic bladder cancer
Flag link:
Allergan says it will shed two drugs as AbbVie takeover looms
Allergan says it will shed two drugs as AbbVie takeover looms
Pharmaforum
Allergan
brazikumab
Zenprep
AbbVie
M&A
Flag link:
AbbVie’s $63B Allergan buyout offer depends on Botox growth. But will it last?
AbbVie’s $63B Allergan buyout offer depends on Botox growth. But will it last?
Fierce Pharma
Allergan
AbbVie
Botox
M&A
Flag link:
These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024
These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024
Yahoo/Motley Fool
Merck
Keytruda
AbbVie
Humira
Pfizer
Bristol-Myers Squibb
Eliquis
JNJ
Imbruvica
Flag link:
5 Things You Need to Know From AbbVie's Q2 Earnings Results
5 Things You Need to Know From AbbVie's Q2 Earnings Results
Motley Fool
AbbVie
Humira
Venclexta
Imbruvica
hepatitis C
earnings
Flag link:
AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib
AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib
Fierce Pharma
AbbVie
Humira
biosimilars
Europe
psoriasis
rheumatoid arthritis
Skyrizi
Flag link:
AbbVie stock up 2% after earnings beat
AbbVie stock up 2% after earnings beat
Marketwatch
AbbVie
earnings
Flag link:

Pages